Welcome to the 2nd Annual Biomarkers for Alzheimer’s Disease Summit
Alzheimer’s Disease is a huge unmet medical need, with more than 5.8 million adults in the U.S. living with Alzheimer's disease, and there are more than 487,000 new cases each year. Yet, there have been no novel treatments approved for since 2003.
This could change with the pending approval of Aducanumab, the world’s first disease-modifying Alzheimer's therapeutic, but there is still a long way to go.
Developing clinically validated biomarkers for earlier detection and diagnosis of Alzheimer’s, that are predictive of outcome measures and accurately reflect a therapeutics’ effect on disease progression, remains ones of the greatest hurdles drug developers need to overcome to develop truly disease modifying therapeutics.
Here to support drug developers, the Biomarkers for Alzheimer’s Disease Summit is the industry’s only forum dedicated to solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of disease, that are predictive of outcome measures and accurately reflect a therapeutics’ effect on target engagement.
Built with the support of thought leaders from Biogen, Eisai, Alector and 20+ other thought-leading biopharma organizations, this definitive summit will enable drug developers to scale the hurdles preventing the clinical validation of biomarkers to enable the development of more effective therapeutics for Alzheimer’s Disease.
Across 3 packed days, 60+ experts will converge at the Biomarkers for Alzheimer’s Disease Summit to share cutting edge advances on assessing combinational approaches to robustly diagnose and identify responsive patient populations, reviewing the global regulatory roadmap to approval and accepted clinical endpoints and comparing novel biomarkers to ascertain which are most clinically meaningful and help drug developers evaluate their drugs' effectivenes.